Switch to:
Also traded in: France, Germany, UK
» Details

Insider Trades

Latest Guru Trades with IPSEY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412 
Compare:OTCPK:HKMPY, NYSE:RDY, NYSE:MNK, NYSE:VRX, OTCPK:HYPMY, OTCPK:HLUYY, NAS:OPK, NYSE:TARO, NYSE:PTHN, OTCPK:SFOSF, NAS:NBIX, OTCPK:STDAF, NAS:MDCO, NYSE:CTLT, OTCPK:INVVY, OTCPK:APNHY, OTCPK:SHPHF, NAS:ENDP, NAS:HZNP, NAS:AKRX » details
Traded in other countries:IPNNV.France, I7G.Germany, 0MH6.UK,
Ipsen SA is a biotechnology specialty care company that produces drugs for uro-oncology, endocrinology, neurology and hematology and primary care.

Ipsen SA was incorporated on July 28, 1998. It is a biotechnology specialty care company. It produces drugs for uro-oncology, endocrinology, neurology and hematology, and primary care. The Company's segments include Major Western European countries, including France, Italy, Spain, the United Kingdom, and Germany; Rest of Europe, including all other Western and Eastern European countries; North America, mainly including the United States; and Rest of the World, encompassing all countries.

Ratios

vs
industry
vs
history
P/E(ttm) 27.77
IPSEY's P/E(ttm) is ranked higher than
50% of the 568 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.40 vs. IPSEY: 27.77 )
Ranked among companies with meaningful P/E(ttm) only.
IPSEY' s P/E(ttm) Range Over the Past 10 Years
Min: 12.7  Med: 21.62 Max: 2433
Current: 27.77
12.7
2433
Forward P/E 20.37
IPSEY's Forward P/E is ranked lower than
66% of the 88 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.46 vs. IPSEY: 20.37 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 27.87
IPSEY's PE(NRI) is ranked higher than
51% of the 543 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.84 vs. IPSEY: 27.87 )
Ranked among companies with meaningful PE(NRI) only.
IPSEY' s PE(NRI) Range Over the Past 10 Years
Min: 12.77  Med: 21.8 Max: 33.72
Current: 27.87
12.77
33.72
Price/Owner Earnings (ttm) 70.82
IPSEY's Price/Owner Earnings (ttm) is ranked lower than
79% of the 300 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.72 vs. IPSEY: 70.82 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
IPSEY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.51  Med: 28.35 Max: 70.82
Current: 70.82
10.51
70.82
P/B 5.15
IPSEY's P/B is ranked lower than
72% of the 827 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.02 vs. IPSEY: 5.15 )
Ranked among companies with meaningful P/B only.
IPSEY' s P/B Range Over the Past 10 Years
Min: 1.53  Med: 3.07 Max: 5.19
Current: 5.15
1.53
5.19
P/S 4.26
IPSEY's P/S is ranked lower than
60% of the 766 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.06 vs. IPSEY: 4.26 )
Ranked among companies with meaningful P/S only.
IPSEY' s P/S Range Over the Past 10 Years
Min: 1.26  Med: 2.57 Max: 4.26
Current: 4.26
1.26
4.26
PFCF 43.66
IPSEY's PFCF is ranked lower than
72% of the 226 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.72 vs. IPSEY: 43.66 )
Ranked among companies with meaningful PFCF only.
IPSEY' s PFCF Range Over the Past 10 Years
Min: 10.06  Med: 23.67 Max: 47.08
Current: 43.66
10.06
47.08
POCF 28.97
IPSEY's POCF is ranked lower than
72% of the 295 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.98 vs. IPSEY: 28.97 )
Ranked among companies with meaningful POCF only.
IPSEY' s POCF Range Over the Past 10 Years
Min: 6.61  Med: 13.78 Max: 28.97
Current: 28.97
6.61
28.97
EV-to-EBIT 26.72
IPSEY's EV-to-EBIT is ranked lower than
63% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.65 vs. IPSEY: 26.72 )
Ranked among companies with meaningful EV-to-EBIT only.
IPSEY' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 15.9 Max: 26.72
Current: 26.72
8.7
26.72
EV-to-EBITDA 22.58
IPSEY's EV-to-EBITDA is ranked lower than
64% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.72 vs. IPSEY: 22.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
IPSEY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 11.7 Max: 22.58
Current: 22.58
7.3
22.58
PEG 2.31
IPSEY's PEG is ranked lower than
58% of the 282 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. IPSEY: 2.31 )
Ranked among companies with meaningful PEG only.
IPSEY' s PEG Range Over the Past 10 Years
Min: 1.43  Med: 4.33 Max: 37.18
Current: 2.31
1.43
37.18
Shiller P/E 52.33
IPSEY's Shiller P/E is ranked lower than
58% of the 158 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 47.37 vs. IPSEY: 52.33 )
Ranked among companies with meaningful Shiller P/E only.
IPSEY' s Shiller P/E Range Over the Past 10 Years
Min: 1.83  Med: 33.71 Max: 52.33
Current: 52.33
1.83
52.33
Current Ratio 2.23
IPSEY's Current Ratio is ranked lower than
55% of the 726 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.49 vs. IPSEY: 2.23 )
Ranked among companies with meaningful Current Ratio only.
IPSEY' s Current Ratio Range Over the Past 10 Years
Min: 1.39  Med: 1.8 Max: 2.33
Current: 2.23
1.39
2.33
Quick Ratio 1.97
IPSEY's Quick Ratio is ranked higher than
53% of the 725 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. IPSEY: 1.97 )
Ranked among companies with meaningful Quick Ratio only.
IPSEY' s Quick Ratio Range Over the Past 10 Years
Min: 1.1  Med: 1.52 Max: 2.03
Current: 1.97
1.1
2.03
Days Inventory 117.10
IPSEY's Days Inventory is ranked lower than
51% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 114.19 vs. IPSEY: 117.10 )
Ranked among companies with meaningful Days Inventory only.
IPSEY' s Days Inventory Range Over the Past 10 Years
Min: 115.36  Med: 160.26 Max: 176.3
Current: 117.1
115.36
176.3
Days Sales Outstanding 77.59
IPSEY's Days Sales Outstanding is ranked lower than
51% of the 628 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.32 vs. IPSEY: 77.59 )
Ranked among companies with meaningful Days Sales Outstanding only.
IPSEY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 66.7  Med: 74.67 Max: 80.25
Current: 77.59
66.7
80.25
Days Payable 208.59
IPSEY's Days Payable is ranked higher than
91% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.12 vs. IPSEY: 208.59 )
Ranked among companies with meaningful Days Payable only.
IPSEY' s Days Payable Range Over the Past 10 Years
Min: 172.18  Med: 201.78 Max: 217.39
Current: 208.59
172.18
217.39

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.18
IPSEY's Dividend Yield is ranked lower than
60% of the 623 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.61 vs. IPSEY: 1.18 )
Ranked among companies with meaningful Dividend Yield only.
IPSEY' s Dividend Yield Range Over the Past 10 Years
Min: 1.1  Med: 2.03 Max: 4.36
Current: 1.18
1.1
4.36
Dividend Payout 0.31
IPSEY's Dividend Payout is ranked higher than
60% of the 375 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.36 vs. IPSEY: 0.31 )
Ranked among companies with meaningful Dividend Payout only.
IPSEY' s Dividend Payout Range Over the Past 10 Years
Min: 0.31  Med: 0.4 Max: 0.91
Current: 0.31
0.31
0.91
Dividend Growth (3y) 2.00
IPSEY's Dividend Growth (3y) is ranked lower than
66% of the 285 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.10 vs. IPSEY: 2.00 )
Ranked among companies with meaningful Dividend Growth (3y) only.
IPSEY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 2.2 Max: 7.7
Current: 2
0
7.7
Forward Dividend Yield 1.18
IPSEY's Forward Dividend Yield is ranked lower than
61% of the 619 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.35 vs. IPSEY: 1.18 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.28
IPSEY's Yield on cost (5-Year) is ranked lower than
65% of the 764 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.14 vs. IPSEY: 1.28 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
IPSEY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.2  Med: 2.22 Max: 4.77
Current: 1.28
1.2
4.77
3-Year Average Share Buyback Ratio 0.40
IPSEY's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 436 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.40 vs. IPSEY: 0.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IPSEY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -42.1  Med: 0.1 Max: 0.9
Current: 0.4
-42.1
0.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 11.20
IPSEY's Price/Tangible Book is ranked lower than
86% of the 747 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.65 vs. IPSEY: 11.20 )
Ranked among companies with meaningful Price/Tangible Book only.
IPSEY' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.69  Med: 5.52 Max: 11.2
Current: 11.2
2.69
11.2
Price/Projected FCF 2.55
IPSEY's Price/Projected FCF is ranked lower than
99.99% of the 320 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. IPSEY: 2.55 )
Ranked among companies with meaningful Price/Projected FCF only.
IPSEY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0  Med: 1.48 Max: 2.55
Current: 2.55
0
2.55
Price/Median PS Value 1.66
IPSEY's Price/Median PS Value is ranked lower than
99.99% of the 703 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. IPSEY: 1.66 )
Ranked among companies with meaningful Price/Median PS Value only.
IPSEY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0  Med: 0.96 Max: 1.66
Current: 1.66
0
1.66
Price/Peter Lynch Fair Value 2.35
IPSEY's Price/Peter Lynch Fair Value is ranked lower than
99.99% of the 168 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.53 vs. IPSEY: 2.35 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
IPSEY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0  Med: 1.83 Max: 3.27
Current: 2.35
0
3.27
Price/Graham Number 3.73
IPSEY's Price/Graham Number is ranked lower than
74% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.25 vs. IPSEY: 3.73 )
Ranked among companies with meaningful Price/Graham Number only.
IPSEY' s Price/Graham Number Range Over the Past 10 Years
Min: 1.53  Med: 2.17 Max: 3.73
Current: 3.73
1.53
3.73
Earnings Yield (Greenblatt) (%) 3.75
IPSEY's Earnings Yield (Greenblatt) (%) is ranked higher than
57% of the 835 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.00 vs. IPSEY: 3.75 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
IPSEY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.75  Med: 6.3 Max: 11.5
Current: 3.75
3.75
11.5
Forward Rate of Return (Yacktman) (%) 16.48
IPSEY's Forward Rate of Return (Yacktman) (%) is ranked higher than
66% of the 358 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.67 vs. IPSEY: 16.48 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
IPSEY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -5.3  Med: 4.8 Max: 17.7
Current: 16.48
-5.3
17.7

More Statistics

Revenue (TTM) (Mil) $1,743
EPS (TTM) $ 0.78
Beta0.63
Short Percentage of Float0.00%
52-Week Range $13.01 - 20.49
Shares Outstanding (Mil)328.51

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,741 1,943 2,091
EPS ($) 0.86 1.00 1.12
EPS w/o NRI ($) 0.86 1.00 1.12
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($) 0.32 0.39 0.43
» More Articles for OTCPK:IPSEY

Headlines

Articles On GuruFocus.com
Wasatch International Growth Fund Comments on Ipsen S.A. Sep 25 2015 
Wasatch International Growth Fund Q2 2015 Shareholder Letter Sep 25 2015 

More From Other Websites
Drugmaker Ipsen to buy some products from Sanofi for 83 million euros Feb 13 2017
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi Feb 13 2017
Ipsen to Acquire a Portfolio of Select Consumer Healthcare Products from Sanofi Feb 13 2017
Sanofi nears deal to sell some over-the-counter drugs to Ipsen - Bloomberg Feb 12 2017
Sanofi Nears Agreement to Sell Some Over-the-Counter Drugs to Ipsen: Source Feb 12 2017
Ipsen Biopharmaceuticals, Inc. Announces Presentations of Dysport® (abobotulinumtoxinA) Data at the... Feb 09 2017
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma Jan 31 2017
Ipsen to Acquire Primary Care Platform in Italy from Akkadeas Pharma Jan 31 2017
Ipsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global... Jan 20 2017
Ipsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global... Jan 20 2017
Merrimack Pharma to Sell Cancer Drugs for $1B Jan 09 2017
Merrimack Soars on $1 Billion Sale of Cancer Drugs to Ipsen Jan 09 2017
France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 billion deal Jan 09 2017
France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 billion deal Jan 09 2017
France's Ipsen to buy Merrimack's pancreatic cancer drug, assets in $1 bln deal Jan 09 2017
Ipsen to buy some Merrimack assets for about $1 billion Jan 08 2017
Ipsen to buy some Merrimack assets for about $1 billion Jan 08 2017
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals Jan 08 2017
Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals Jan 08 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK